Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Simbols: 002399.SZ
SHZ
9.37
CNYTirgus cena šodien
-17.2720
P/E koeficients
-0.4195
PEG koeficients
12.33B
MRK Cap
- 0.01%
DIV ienesīgums
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399-SZ) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10139.37 | 2265.8 | 3450.4 | 3925.4 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 1631.92 | 414.2 | 1311.6 | 981.2 | ||||||||||||||||||
balance-sheet.row.net-receivables | 6253.86 | 1528.6 | 1946.6 | 1985.5 | ||||||||||||||||||
balance-sheet.row.inventory | 30150.6 | 6654.1 | 6843.9 | 4707.5 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 857.6 | 155.4 | 148.7 | 151.2 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 47401.43 | 10603.9 | 12389.6 | 10769.7 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 10261.67 | 2634.2 | 2477.3 | 2537.2 | ||||||||||||||||||
balance-sheet.row.goodwill | 9504.81 | 2322.4 | 2351 | 2152.2 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 2153.33 | 493.2 | 571.7 | 586.7 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 11658.14 | 2815.6 | 2922.6 | 2738.9 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 8198.95 | 2514.9 | 1152.5 | 1636.7 | ||||||||||||||||||
balance-sheet.row.tax-assets | 753.39 | 320.5 | 139.6 | 121.7 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 2460.85 | 314.3 | 1732.5 | 1304.1 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 33333 | 8599.5 | 8424.6 | 8338.5 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 80734.43 | 19203.4 | 20814.2 | 19108.2 | ||||||||||||||||||
balance-sheet.row.account-payables | 1374.71 | 302.2 | 427.4 | 385.8 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 14923.61 | 3662.4 | 4056.5 | 3299.9 | ||||||||||||||||||
balance-sheet.row.tax-payables | 525.27 | 157.2 | 141.8 | 158.7 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 8990.3 | 1810 | 2407.4 | 2354.3 | ||||||||||||||||||
Deferred Revenue Non Current | 127.65 | 30.4 | 32.5 | 16.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1232.54 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 3123.05 | 655.4 | 658 | 3.8 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 10620.06 | 2198 | 2830.8 | 2793.4 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 383.85 | 90.4 | 110.7 | 104 | ||||||||||||||||||
balance-sheet.row.total-liab | 31250.86 | 7184.2 | 8406.6 | 7584.9 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 5869.18 | 1467.3 | 1467.3 | 1467.3 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 14530.6 | 1543.2 | 4314.1 | 3647 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 9077.94 | 1373.8 | 843.4 | 563.9 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 19614.97 | 7528.9 | 5686.1 | 5733.2 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 49092.69 | 11913.1 | 12310.9 | 11411.4 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 80734.43 | 19203.4 | 20814.2 | 19108.2 | ||||||||||||||||||
balance-sheet.row.minority-interest | 360.05 | 75.2 | 96.7 | 112 | ||||||||||||||||||
balance-sheet.row.total-equity | 49452.73 | 11988.4 | 12407.6 | 11523.3 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 80734.43 | - | - | - | ||||||||||||||||||
Total Investments | 9830.87 | 2929.1 | 2464.1 | 2617.8 | ||||||||||||||||||
balance-sheet.row.total-debt | 24004.33 | 5562.8 | 6463.9 | 5654.2 | ||||||||||||||||||
balance-sheet.row.net-debt | 15496.87 | 3711.2 | 4325.1 | 2709.9 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -783.26 | -783.3 | 714.7 | 233.4 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 371.05 | 384.7 | 307.7 | 302.7 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 3.98 | -237.6 | -43.3 | -170.6 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -1332.4 | 43.3 | 0.2 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | -349.12 | -563.1 | -2311.3 | -1125.1 | ||||||||||||||||||
cash-flows.row.account-receivables | 270.55 | 270.5 | -176.1 | 141.8 | ||||||||||||||||||
cash-flows.row.inventory | -619.67 | -619.7 | -2151.6 | -1520.2 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -213.9 | 59.7 | 423.9 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | -43.3 | -170.6 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 548.74 | 3003.1 | 532.3 | 752.7 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 678.73 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -444.88 | -444.9 | -222.4 | -193.9 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 2.34 | -4.9 | 0 | 1.7 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -677.26 | -758.2 | -4482.7 | -2370.2 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1647.35 | 2349.3 | 4210.7 | 3305.1 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 694.02 | -0.1 | 744.2 | -22.9 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 1221.57 | 1141.2 | 249.8 | 719.9 | ||||||||||||||||||
cash-flows.row.debt-repayment | -5991.71 | -730.9 | -6036.3 | -3730.6 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -425.89 | -146.7 | -251 | -412.5 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 5207.43 | -325.4 | 6616.8 | 3642 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -1210.17 | -1203 | 329.6 | -501.1 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 36.32 | 36.3 | 17.3 | -62.8 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 445.94 | -287.1 | -159.9 | 149.4 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 6714.63 | 1851.6 | 1319.7 | 1479.6 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 6268.69 | 2138.8 | 1479.6 | 1330.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 678.73 | 471.4 | -756.6 | -6.6 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -444.88 | -444.9 | -222.4 | -193.9 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 233.86 | 26.5 | -979 | -200.5 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 5434.47 | 5421.7 | 7159.4 | 6365.2 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 3670.52 | 3746.3 | 4825 | 4332.1 | ||||||||||||||||||
income-statement-row.row.gross-profit | 1763.95 | 1675.4 | 2334.4 | 2033 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 179.91 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 458.57 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 517.42 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -985.68 | -855.4 | 294.7 | 274.9 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 2128.44 | 1935.4 | 1211.9 | 1068.9 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 5798.96 | 5681.6 | 6036.9 | 5401 | ||||||||||||||||||
income-statement-row.row.interest-income | -39.52 | -39.5 | 54.1 | 54.9 | ||||||||||||||||||
income-statement-row.row.interest-expense | 223.22 | 223.2 | 235.2 | 201.6 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 517.42 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -89.2 | -220.4 | -305.3 | -550.9 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -985.68 | -855.4 | 294.7 | 274.9 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | -89.2 | -220.4 | -305.3 | -550.9 | ||||||||||||||||||
income-statement-row.row.interest-expense | 223.22 | 223.2 | 235.2 | 201.6 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 241.34 | 384.7 | 307.7 | 302.7 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -433.09 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -674.43 | -259.9 | 1135.1 | 773.2 | ||||||||||||||||||
income-statement-row.row.income-before-tax | -763.62 | -480.4 | 829.9 | 222.3 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | -126.17 | -126.2 | 115.2 | -11.1 | ||||||||||||||||||
income-statement-row.row.net-income | -783.26 | -783.3 | 727.4 | 240.8 |
Biežāk uzdotie jautājumi
Kas ir Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) kopējie aktīvi?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) kopējie aktīvi ir 19203415131.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 2721572551.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.325.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 0.159.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -0.144.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -0.124.
Kāda ir Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -783258039.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 5562816036.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 1935358054.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 1851642224.000.